Double-faceted mechanism of parvoviral oncosuppression
- PMID: 25841215
- DOI: 10.1016/j.coviro.2015.03.008
Double-faceted mechanism of parvoviral oncosuppression
Abstract
The H-1 parvovirus (H-1PV) exerts oncosuppressive action that has two components: oncotoxicity and immunostimulation. While many human tumor cells, including conventional drug-resistant ones, can be killed by H-1PV, some fail to support progeny virus production, necessary for infection propagation in neoplastic tissues. This limitation can be overcome through forced selection of H-1PV variants capable of enhanced multiplication and spreading in human tumor cells. In the context of further developing H-1PV for use in cancer therapy, arming it with immunostimulatory CpG motifs under conditions preserving replication and oncolysis enhances its action as an anticancer vaccine adjuvant. A first clinical study of H-1PV treatment in glioma patients has yielded evidence of intratumoral synthesis of the viral oncotoxic protein NS1 and immune cell infiltration.
Copyright © 2015 Elsevier B.V. All rights reserved.
Similar articles
-
Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model.Oncol Rep. 2007 Jun;17(6):1493-9. Oncol Rep. 2007. PMID: 17487410
-
Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection.J Biomed Biotechnol. 2010;2010:350748. doi: 10.1155/2010/350748. Epub 2010 Mar 7. J Biomed Biotechnol. 2010. PMID: 20224643 Free PMC article.
-
Therapeutic implications of the enhanced short and long-term cytotoxicity of radiation treatment followed by oncolytic parvovirus H-1 infection in high-grade glioma cells.Bioeng Bugs. 2010 Nov-Dec;1(6):429-33. doi: 10.4161/bbug.1.6.12943. Bioeng Bugs. 2010. PMID: 21468212 Free PMC article.
-
Oncolytic parvoviruses as cancer therapeutics.Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):185-95. doi: 10.1016/j.cytogfr.2010.02.011. Epub 2010 Mar 7. Cytokine Growth Factor Rev. 2010. PMID: 20211577 Review.
-
Oncolytic bovine herpesvirus type 1 as a broad spectrum cancer therapeutic.Curr Opin Virol. 2015 Aug;13:11-6. doi: 10.1016/j.coviro.2015.03.010. Epub 2015 Apr 2. Curr Opin Virol. 2015. PMID: 25846987 Review.
Cited by
-
The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers.Front Oncol. 2017 May 12;7:93. doi: 10.3389/fonc.2017.00093. eCollection 2017. Front Oncol. 2017. PMID: 28553616 Free PMC article.
-
Current Progress in Vaccines against Merkel Cell Carcinoma: A Narrative Review and Update.Vaccines (Basel). 2024 May 13;12(5):533. doi: 10.3390/vaccines12050533. Vaccines (Basel). 2024. PMID: 38793784 Free PMC article. Review.
-
Immune System Stimulation by Oncolytic Rodent Protoparvoviruses.Viruses. 2019 May 4;11(5):415. doi: 10.3390/v11050415. Viruses. 2019. PMID: 31060205 Free PMC article. Review.
-
Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.Front Immunol. 2019 Aug 7;10:1848. doi: 10.3389/fimmu.2019.01848. eCollection 2019. Front Immunol. 2019. PMID: 31440242 Free PMC article. Review.
-
The Oncolytic Virus in Cancer Diagnosis and Treatment.Front Oncol. 2020 Sep 9;10:1786. doi: 10.3389/fonc.2020.01786. eCollection 2020. Front Oncol. 2020. Retraction in: Front Oncol. 2023 Nov 10;13:1320477. doi: 10.3389/fonc.2023.1320477. PMID: 33014876 Free PMC article. Retracted. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
